TNGX Q2 2023 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+153.0% YoY

Gross Profit

$13M89.7% margin

Operating Income

-$23M-159.2% margin

Net Income

-$21M-141.9% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+153.2%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$25M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$379M

Total Liabilities

$166M

Stockholders' Equity

$213M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$6M	+153.0%
Gross Profit	$13M	$5M	+157.4%
Operating Income	-$23M	-$25M	+7.8%
Net Income	-$21M	-$25M	+16.7%

Revenue Segments

Collaboration Revenue

$10M66%

License Revenue

$5M34%